Gastric cancer (GC), notorious for its poor prognosis, often advances to peritoneal dissemination, a crucial determinant of detrimental outcomes. This study intricately explores the role of the TGFβ-Smad-LIF axis within the tumor microenvironment in propagating peritoneal metastasis, with a specific emphasis on its molecular mechanism in instigating Neutrophil Extracellular Traps (NETs) formation and encouraging GC cellular functions. Through a blend of bioinformatics analyses, utilizing TCGA and GEO databases, and meticulous in vivo and in vitro experiments, LIF was identified as pivotally associated with GC metastasis, notably, enhancing the NETs formation through neutrophil stimulation. Mechanistically, TGF-β was substantiated to elevate LIF expression via the activation of the Smad2/3 complex, culminating in NETs formation and consequently, propelling peritoneal metastasis of GC. This revelation uncovers a novel potential therapeutic target, promising a new avenue in managing GC and mitigating its metastatic propensities.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10943116 | PMC |
| http://dx.doi.org/10.1038/s41419-024-06594-w | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Laparoscopic surgery is associated with increased risk of postoperative peritoneal metastases in T4 colon cancer: a propensity score analysis.
Int J Colorectal Dis
January 2025
Department of Colorectal Surgery, the First Affiliated Hospital of Naval Medical University, Shanghai, 200433, China.
Background: This study aims to evaluate the postoperative safety, long-term survival, and postoperative peritoneal metastases (PPM) rate associated with laparoscopic surgery (LS) for T4 colon cancer.
Materials And Methods: After propensity score matching, there were 68 patients in each of the LS and Open surgery groups. The primary outcomes were the 3-year OS, DFS, and PPM rates.
Incidence, Clinicopathological Features, and Outcomes of Signet Ring Colorectal Carcinoma: A Retrospective Study.
Cureus
December 2024
Department of Surgical Oncology, Shaukat Khanum Memorial Cancer Hospital and Research Centre, Lahore, PAK.
Background Signet ring cell carcinoma (SRCC) is a rare subtype of colorectal cancer with significant variations in clinical characteristics and poor prognosis. However, there is limited data available in Pakistan. Therefore, we analyzed to examine the incidence, clinicopathological features, treatments, and outcomes of SRCC in colorectal cancer cases in Pakistan.
View Article and Find Full Text PDFComment on "Effect of systemic FOLFOXIRI plus bevacizumab treatment of colorectal peritoneal metastasis on local and systemic immune cells".
Surgery
December 2024
Department of Colorectal Surgery, Ningbo No. 2 Hospital, Ningbo, Zhejiang, China. Electronic address:
Development of a Prognostic Model for Stage IV Colorectal Cancer Using Metastatic Patterns.
Anticancer Res
January 2025
Department of Minimally Invasive Surgical and Medical Oncology, Fukushima Medical University, Koriyama, Japan.
Background/aim: Metastatic patterns are the most convenient and common prediction models for the prognosis of patients with stage IV colorectal cancer. However, current prediction models do not include the severity of metastases in organs and exclude certain types of metastatic patterns. The aim of this study was to develop a prediction model that included several metastatic organs as well as the severity of liver and lung metastases, based on the Japanese Classification of Colorectal, Appendiceal, and Anal Carcinoma: the 3 English Edition.
View Article and Find Full Text PDFEnrichment of Cancer-Associated Fibroblasts, Macrophages, and Up-Regulated TNF-α Signaling in the Tumor Microenvironment of CMS4 Colorectal Peritoneal Metastasis.
Cancer Med
January 2025
Department of Tumor Biology, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.
Background: Metastatic colorectal cancer (mCRC) is the main cause of CRC mortality, with limited treatment options. Although immunotherapy has benefited some cancer patients, mCRC typically lacks the molecular features that respond to this treatment. However, recent studies indicate that the immune microenvironment of mCRC may be modified to enhance the effect of immune checkpoint inhibitors.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!